A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors (NCT07300150)
A Phase 1, Open-label Dose Escalation and Expansion Study Of PT0511 in Participants With KRAS Mutated OR Amplified Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0511 in adult participants with solid tumors as monotherapy and in combination with cetuximab in participants with colorectal cancer (CRC).
Who can join: Review the eligibility criteria below.
Location: Dana-Farber/Massachusetts General Hospital, Inc — Boston, Massachusetts
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (9 Sites)
- Dana-Farber/Massachusetts General Hospital, Inc — Boston, Massachusetts
- New Experimental Therapeutics of San Antonio LLC — San Antonio, Texas
- START - South Texas Accelerated Research Therapeutics, LLC — San Antonio, Texas
- START Mountain Region — West Valley City, Utah
- NEXT Virginia — Fairfax, Virginia
- Samsung Medical Center — Seoul,
- Seoul National University Bundang Hospital — Seoul,
- Seoul National University Hospital — Seoul,
- Severance Hospital, Yonsei University Health System — Seoul,
📞 Contact the Study Coordinator
Phone: (781) 819-2949
Email: ClinicalTrials@paqtx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Colorectal Cancer
- Impact of Colorectal Cancer and Nutrition Education Program Among Minority Patients With Type 2 Diabetes — Los Angeles, California
- A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors — Duarte, California
- Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD) — Houston, Texas
- Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver — Basking Ridge, New Jersey
- The PRIME-CRC Trial to Promote CRC Screening in Rural Communities — Bastrop, Louisiana
- Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer — Concord, California
Explore by condition: All Colorectal Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.